Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Straylight As The Result Of Refractive Correction.

Gaurisankar ZS, van Rijn GA, Luyten GP, van den Berg TJ.

Clin Ophthalmol. 2019 Nov 12;13:2195-2201. doi: 10.2147/OPTH.S224970. eCollection 2019.

2.

Aqueous Humor Biomarkers Identify Three Prognostic Groups in Uveal Melanoma.

Wierenga APA, Cao J, Mouthaan H, van Weeghel C, Verdijk RM, van Duinen SG, Kroes WGM, Dogrusöz M, Marinkovic M, van der Burg SSH, Luyten GPM, Jager MJ.

Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4740-4747. doi: 10.1167/iovs.19-28309.

PMID:
31731294
3.

Reaction on "Ocular ultrasound versus MRI in the detection of extrascleral extension in a patient with choroidal melanoma".

Jaarsma-Coes MG, Ferreira TA, Luyten GPM, Beenakker JWM.

BMC Ophthalmol. 2019 Aug 27;19(1):193. doi: 10.1186/s12886-019-1206-y.

4.

Soluble HLA in the Aqueous Humour of Uveal Melanoma Is Associated with Unfavourable Tumour Characteristics.

Wierenga APA, Gezgin G, van Beelen E, Eikmans M, Spruyt-Gerritse M, Brouwer NJ, Versluis M, Verdijk RM, van Duinen SG, Marinkovic M, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 18;11(8). pii: E1202. doi: 10.3390/cancers11081202.

5.

Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?

van Weeghel C, Wierenga APA, Versluis M, van Hall T, van der Velden PA, Kroes WGM, Pfeffer U, Luyten GPM, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1127. doi: 10.3390/cancers11081127.

6.

Correlations between ocular biometrics and refractive error: A systematic review and meta-analysis.

Gaurisankar ZS, van Rijn GA, Lima JEE, Ilgenfritz AP, Cheng Y, Haasnoot GW, Luyten GPM, Beenakker JM.

Acta Ophthalmol. 2019 Dec;97(8):735-743. doi: 10.1111/aos.14208. Epub 2019 Aug 6. Review.

PMID:
31386806
7.

Families with BAP1-Tumor Predisposition Syndrome in The Netherlands: Path to Identification and a Proposal for Genetic Screening Guidelines.

Chau C, van Doorn R, van Poppelen NM, van der Stoep N, Mensenkamp AR, Sijmons RH, van Paassen BW, van den Ouweland AMW, Naus NC, van der Hout AH, Potjer TP, Bleeker FE, Wevers MR, van Hest LP, Jongmans MCJ, Marinkovic M, Bleeker JC, Jager MJ, Luyten GPM, Nielsen M.

Cancers (Basel). 2019 Aug 4;11(8). pii: E1114. doi: 10.3390/cancers11081114.

8.

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma.

Dogrusöz M, Ruschel Trasel A, Cao J, Ҫolak S, van Pelt SI, Kroes WGM, Teunisse AFAS, Alsafadi S, van Duinen SG, Luyten GPM, van der Velden PA, Amaro A, Pfeffer U, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1104. doi: 10.3390/cancers11081104.

9.

Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma.

Souri Z, Wierenga APA, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, van der Burg SH, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1102. doi: 10.3390/cancers11081102.

10.

Two Late Recurrences of Conjunctival Melanoma.

Brouwer NJ, Genders SW, Marinkovic M, van Duinen SG, Jager MJ, Luyten GPM.

Ocul Oncol Pathol. 2019 Jun;5(4):262-266. doi: 10.1159/000494978. Epub 2018 Dec 12.

11.

Tumour Angiogenesis in Uveal Melanoma Is Related to Genetic Evolution.

Brouwer NJ, Gezgin G, Wierenga APA, Bronkhorst IHG, Marinkovic M, Luyten GPM, Versluis M, Kroes WGM, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 13;11(7). pii: E979. doi: 10.3390/cancers11070979.

12.

Ischemia Is Related to Tumour Genetics in Uveal Melanoma.

Brouwer NJ, Wierenga APA, Gezgin G, Marinkovic M, Luyten GPM, Kroes WGM, Versluis M, van der Velden PA, Verdijk RM, Jager MJ.

Cancers (Basel). 2019 Jul 18;11(7). pii: E1004. doi: 10.3390/cancers11071004.

13.

Pigmentation of conjunctival melanoma recurrences and outcome.

Brouwer NJ, Marinkovic M, Luyten GPM, Shields CL, Jager MJ.

Graefes Arch Clin Exp Ophthalmol. 2019 Aug;257(8):1783-1788. doi: 10.1007/s00417-019-04342-x. Epub 2019 May 16.

PMID:
31098751
14.

Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma.

Wierenga APA, Cao J, Luyten GPM, Jager MJ.

Int Ophthalmol Clin. 2019 Spring;59(2):53-63. doi: 10.1097/IIO.0000000000000263. Review. No abstract available.

PMID:
30908279
15.

Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide.

Walpole S, Pritchard AL, Cebulla CM, Pilarski R, Stautberg M, Davidorf FH, de la Fouchardière A, Cabaret O, Golmard L, Stoppa-Lyonnet D, Garfield E, Njauw CN, Cheung M, Turunen JA, Repo P, Järvinen RS, van Doorn R, Jager MJ, Luyten GPM, Marinkovic M, Chau C, Potrony M, Höiom V, Helgadottir H, Pastorino L, Bruno W, Andreotti V, Dalmasso B, Ciccarese G, Queirolo P, Mastracci L, Wadt K, Kiilgaard JF, Speicher MR, van Poppelen N, Kilic E, Al-Jamal RT, Dianzani I, Betti M, Bergmann C, Santagata S, Dahiya S, Taibjee S, Burke J, Poplawski N, O'Shea SJ, Newton-Bishop J, Adlard J, Adams DJ, Lane AM, Kim I, Klebe S, Racher H, Harbour JW, Nickerson ML, Murali R, Palmer JM, Howlie M, Symmons J, Hamilton H, Warrier S, Glasson W, Johansson P, Robles-Espinoza CD, Ossio R, de Klein A, Puig S, Ghiorzo P, Nielsen M, Kivelä TT, Tsao H, Testa JR, Gerami P, Stern MH, Paillerets BB, Abdel-Rahman MH, Hayward NK.

J Natl Cancer Inst. 2018 Dec 1;110(12):1328-1341. doi: 10.1093/jnci/djy171. Review.

16.

Conjunctival Metastasis of a Cutaneous Melanoma.

Brouwer NJ, Marinkovic M, Jochems A, Kapiteijn EW, van Duinen SG, Haeseker BI, Jager MJ, Luyten GPM.

Ocul Oncol Pathol. 2018 Sep;4(2):107-111. doi: 10.1159/000479114. Epub 2017 Sep 1.

17.

CT and MR imaging of orbital inflammation.

Ferreira TA, Saraiva P, Genders SW, Buchem MV, Luyten GPM, Beenakker JW.

Neuroradiology. 2018 Dec;60(12):1253-1266. doi: 10.1007/s00234-018-2103-4. Epub 2018 Oct 11. Review.

18.

Quality of life: fractionated stereotactic radiotherapy versus enucleation treatment in uveal melanoma patients.

van Beek JGM, Buitendijk GHS, Timman R, Muller K, Luyten GPM, Paridaens D, Naus NC, Kiliç E.

Acta Ophthalmol. 2018 Dec;96(8):841-848. doi: 10.1111/aos.13823. Epub 2018 Oct 3.

19.

Digital PCR-Based T-cell Quantification-Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma.

de Lange MJ, Nell RJ, Lalai RN, Versluis M, Jordanova ES, Luyten GPM, Jager MJ, van der Burg SH, Zoutman WH, van Hall T, van der Velden PA.

Mol Cancer Res. 2018 Dec;16(12):1902-1911. doi: 10.1158/1541-7786.MCR-18-0114. Epub 2018 Aug 9.

20.

Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy.

Mohabati D, van Rijssen TJ, van Dijk EH, Luyten GP, Missotten TO, Hoyng CB, Yzer S, Boon CJ.

Clin Ophthalmol. 2018 Jun 7;12:1061-1070. doi: 10.2147/OPTH.S160956. eCollection 2018.

21.

Lack of tumour pigmentation in conjunctival melanoma is associated with light iris colour and worse prognosis.

Brouwer NJ, Marinkovic M, Luyten GPM, Shields CL, Jager MJ.

Br J Ophthalmol. 2019 Mar;103(3):332-337. doi: 10.1136/bjophthalmol-2018-312018. Epub 2018 May 18.

PMID:
29777046
22.

Pimasertib-associated ophthalmological adverse events.

van Dijk EHC, Kruit WHJ, Jager MJ, Luyten GPM, Vingerling JR, Boon CJF.

Acta Ophthalmol. 2018 Nov;96(7):712-718. doi: 10.1111/aos.13677. Epub 2018 Jan 16.

23.

Ruthenium-106 brachytherapy for iris and iridociliary melanomas.

Marinkovic M, Horeweg N, Laman MS, Bleeker JC, Ketelaars M, Peters FP, Luyten GPM, Creutzberg CL.

Br J Ophthalmol. 2018 Aug;102(8):1154-1159. doi: 10.1136/bjophthalmol-2017-310688. Epub 2017 Nov 9.

PMID:
29122824
24.

Treatment of conjunctival melanoma in a Dutch referral centre.

Brouwer NJ, Marinkovic M, van Duinen SG, Bleeker JC, Jager MJ, Luyten GPM.

Br J Ophthalmol. 2018 Sep;102(9):1277-1282. doi: 10.1136/bjophthalmol-2017-311082. Epub 2017 Nov 9.

PMID:
29122819
25.

Multiple Pigmented Conjunctival Lesions following Intravitreal Injections in a Patient with Uveal Melanoma.

Brouwer NJ, Luyten GPM, van Duinen SG, Jager MJ, Marinkovic M.

Ocul Oncol Pathol. 2017 Jul;3(2):113-116. doi: 10.1159/000452447. Epub 2016 Nov 9.

26.

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ.

JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729.

27.

Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.

Gezgin G, Dogrusöz M, van Essen TH, Kroes WGM, Luyten GPM, van der Velden PA, Walter V, Verdijk RM, van Hall T, van der Burg SH, Jager MJ.

Cancer Immunol Immunother. 2017 Jul;66(7):903-912. doi: 10.1007/s00262-017-1991-1. Epub 2017 Apr 8.

28.

A translucent vascularised iris granuloma in a patient with secondary syphilis.

de Jong Y, Haverkort ME, van Sorge AJ, Jansen C, Luyten GP, Joosse M.

Lancet Infect Dis. 2017 Mar;17(3):255-256. doi: 10.1016/S1473-3099(17)30071-3. Epub 2017 Feb 23. No abstract available.

PMID:
28244379
29.

The Prognostic Value of AJCC Staging in Uveal Melanoma Is Enhanced by Adding Chromosome 3 and 8q Status.

Dogrusöz M, Bagger M, van Duinen SG, Kroes WG, Ruivenkamp CA, Böhringer S, Andersen KK, Luyten GP, Kiilgaard JF, Jager MJ.

Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):833-842. doi: 10.1167/iovs.16-20212.

PMID:
28159971
30.

Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.

de Leede EM, Burgmans MC, Kapiteijn E, Luyten GP, Jager MJ, Tijl FG, Hartgrink HH, Grünhagen DJ, Rothbarth J, van de Velde CJ, Verhoef C, Vahrmeijer AL.

Melanoma Res. 2016 Dec;26(6):588-594.

PMID:
27513071
31.

Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia.

Tideman JW, Snabel MC, Tedja MS, van Rijn GA, Wong KT, Kuijpers RW, Vingerling JR, Hofman A, Buitendijk GH, Keunen JE, Boon CJ, Geerards AJ, Luyten GP, Verhoeven VJ, Klaver CC.

JAMA Ophthalmol. 2016 Dec 1;134(12):1355-1363. doi: 10.1001/jamaophthalmol.2016.4009.

PMID:
27768171
32.

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes.

van Essen TH, van Pelt SI, Bronkhorst IH, Versluis M, Némati F, Laurent C, Luyten GP, van Hall T, van den Elsen PJ, van der Velden PA, Decaudin D, Jager MJ.

PLoS One. 2016 Oct 20;11(10):e0164292. doi: 10.1371/journal.pone.0164292. eCollection 2016.

33.

Ruthenium-106 brachytherapy for choroidal melanoma without transpupillary thermotherapy: Similar efficacy with improved visual outcome.

Marinkovic M, Horeweg N, Fiocco M, Peters FP, Sommers LW, Laman MS, Bleeker JC, Ketelaars M, Luyten GP, Creutzberg CL.

Eur J Cancer. 2016 Nov;68:106-113. doi: 10.1016/j.ejca.2016.09.009. Epub 2016 Oct 12.

PMID:
27741435
34.

[A woman with iris heterochromia].

Birker IL, Boons LS, Luyten GP.

Ned Tijdschr Geneeskd. 2016;160:D197. Dutch.

PMID:
27334084
35.

Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients.

van Dijk EH, Duits DE, Versluis M, Luyten GP, Bergen AA, Kapiteijn EW, de Lange MJ, Boon CJ, van der Velden PA.

Medicine (Baltimore). 2016 May;95(18):e3457. doi: 10.1097/MD.0000000000003457.

36.

Clinical evaluation of ultra-high-field MRI for three-dimensional visualisation of tumour size in uveal melanoma patients, with direct relevance to treatment planning.

Beenakker JW, Ferreira TA, Soemarwoto KP, Genders SW, Teeuwisse WM, Webb AG, Luyten GP.

MAGMA. 2016 Jun;29(3):571-7. doi: 10.1007/s10334-016-0529-4. Epub 2016 Feb 25.

37.

Donor sclera-wrapped acrylic orbital implants following enucleation: experience in 179 patients in the Netherlands.

Jongman HP, Marinkovic M, Notting I, Koetsier L, Swart W, Schalij-Delfos NE, Bleeker J, Jager MJ, Luyten GP.

Acta Ophthalmol. 2016 May;94(3):253-6. doi: 10.1111/aos.12960. Epub 2016 Feb 23.

38.

Biocompatibility of a fish scale-derived artificial cornea: Cytotoxicity, cellular adhesion and phenotype, and in vivo immunogenicity.

van Essen TH, van Zijl L, Possemiers T, Mulder AA, Zwart SJ, Chou CH, Lin CC, Lai HJ, Luyten GPM, Tassignon MJ, Zakaria N, El Ghalbzouri A, Jager MJ.

Biomaterials. 2016 Mar;81:36-45. doi: 10.1016/j.biomaterials.2015.11.015. Epub 2015 Dec 1.

PMID:
26717247
39.

Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

de Lange MJ, van Pelt SI, Versluis M, Jordanova ES, Kroes WG, Ruivenkamp C, van der Burg SH, Luyten GP, van Hall T, Jager MJ, van der Velden PA.

Oncotarget. 2015 Nov 10;6(35):37824-35. doi: 10.18632/oncotarget.5637.

40.

Radiation Treatment Affects Chromosome Testing in Uveal Melanoma.

Dogrusöz M, Kroes WG, van Duinen SG, Creutzberg CL, Versluis M, Bleeker JC, Marinkovic M, Luyten GP, Jager MJ.

Invest Ophthalmol Vis Sci. 2015 Sep;56(10):5956-64. doi: 10.1167/iovs.15-17092.

PMID:
26393462
41.

Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.

de Lange MJ, Razzaq L, Versluis M, Verlinde S, Dogrusöz M, Böhringer S, Marinkovic M, Luyten GP, de Keizer RJ, de Gruijl FR, Jager MJ, van der Velden PA.

PLoS One. 2015 Sep 14;10(9):e0138002. doi: 10.1371/journal.pone.0138002. eCollection 2015.

42.

Dutch Translation and Psychometric Testing of the 9-Item Shared Decision Making Questionnaire (SDM-Q-9) and Shared Decision Making Questionnaire-Physician Version (SDM-Q-Doc) in Primary and Secondary Care.

Rodenburg-Vandenbussche S, Pieterse AH, Kroonenberg PM, Scholl I, van der Weijden T, Luyten GP, Kruitwagen RF, den Ouden H, Carlier IV, van Vliet IM, Zitman FG, Stiggelbout AM.

PLoS One. 2015 Jul 7;10(7):e0132158. doi: 10.1371/journal.pone.0132158. eCollection 2015.

43.

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.

van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ.

Ophthalmology. 2015 Sep;122(9):1907-16. doi: 10.1016/j.ophtha.2015.05.027. Epub 2015 Jun 26.

PMID:
26123090
44.

The genetic basis of uveal melanoma.

Nielsen M, Dogrusöz M, Bleeker JC, Kroes WG, van Asperen CA, Marinkovic M, Luyten GP, Jager MJ.

J Fr Ophtalmol. 2015 Jun;38(6):516-21. doi: 10.1016/j.jfo.2015.04.003. Epub 2015 May 11.

PMID:
25976137
45.

Digital PCR validates 8q dosage as prognostic tool in uveal melanoma.

Versluis M, de Lange MJ, van Pelt SI, Ruivenkamp CA, Kroes WG, Cao J, Jager MJ, Luyten GP, van der Velden PA.

PLoS One. 2015 Mar 12;10(3):e0116371. doi: 10.1371/journal.pone.0116371. eCollection 2015.

46.

Automated retinal topographic maps measured with magnetic resonance imaging.

Beenakker JW, Shamonin DP, Webb AG, Luyten GP, Stoel BC.

Invest Ophthalmol Vis Sci. 2015 Jan 15;56(2):1033-9. doi: 10.1167/iovs.14-15161.

PMID:
25593030
47.

Prognostic parameters in uveal melanoma and their association with BAP1 expression.

van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, Harbour JW, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ.

Br J Ophthalmol. 2014 Dec;98(12):1738-43. doi: 10.1136/bjophthalmol-2014-305047. Epub 2014 Aug 21.

48.

Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma.

Bronkhorst IH, Jehs TM, Dijkgraaf EM, Luyten GP, van der Velden PA, van der Burg SH, Jager MJ.

JAMA Ophthalmol. 2014 May;132(5):614-21.

PMID:
24626595
49.

High-resolution MRI of uveal melanoma using a microcoil phased array at 7 T.

Beenakker JW, van Rijn GA, Luyten GP, Webb AG.

NMR Biomed. 2013 Dec;26(12):1864-9. doi: 10.1002/nbm.3041. Epub 2013 Oct 7.

PMID:
24123279
50.

Implantation of phakic intraocular lens in 3 patients with oculocutaneous albinism.

van Rijn GA, Snoek C, Joosse M, Saxena R, Luyten GP.

J Cataract Refract Surg. 2013 Oct;39(10):1604-8. doi: 10.1016/j.jcrs.2013.08.008.

PMID:
24075162

Supplemental Content

Loading ...
Support Center